Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-3.42	-9.52	-0.29	-7.81	-4.69
Depreciation & Amortization	7	7.58	7.62	7.63	7.73
Share-Based Compensation	5	4.41	4.17	3.65	3.03
Other Operating Activities	5.45	-1.32	-10.24	5.86	1.97
Operating Cash Flow	14.03	1.15	1.26	9.33	8.05
Operating Cash Flow Growth	1117.71%	-8.72%	-86.48%	15.99%	178.95%
Capital Expenditures	-2.31	-1.59	-1.2	-1.15	-1.22
Acquisitions	0.51	0	0	0	1
Other Investing Activities	-	-	-0.15	-0.25	-0.02
Investing Cash Flow	-1.8	-1.59	-1.35	-1.4	-0.23
Share Issuance / Repurchase	0.93	0.58	3.31	0.67	0
Debt Issued / Paid	-10.54	-1.79	-0.05	-7.49	-7.4
Other Financing Activities	-2.52	-1.63	-3.51	-1.14	-0.22
Financing Cash Flow	-12.13	-2.84	-0.25	-7.97	-7.62
Exchange Rate Effect	-0.32	-0.04	-0.16	0.02	-0.03
Net Cash Flow	-0.23	-3.31	-0.5	-0.02	0.16
Free Cash Flow	11.72	-0.44	0.07	8.18	6.83
Free Cash Flow Growth	-	-	-99.18%	19.77%	259.80%
Free Cash Flow Margin	10.44%	-0.39%	0.06%	8.01%	5.88%
Free Cash Flow Per Share	0.28	-0.01	0.00	0.21	0.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).